These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 28286977)

  • 41. Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
    Ingram MA; Lauren BN; Pumpalova Y; Park J; Lim F; Bates SE; Kastrinos F; Manji GA; Kong CY; Hur C
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1565. PubMed ID: 35122419
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
    Zhang H; Kellett C; Lambert P; Kim CA
    Clin Colorectal Cancer; 2018 Sep; 17(3):e451-e456. PubMed ID: 29631907
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel.
    Shibuki T; Otsuka T; Shimokawa M; Nakazawa J; Arima S; Fukahori M; Miwa K; Okabe Y; Koga F; Ueda Y; Kubotsu Y; Makiyama A; Shimokawa H; Takeshita S; Nishikawa K; Komori A; Otsu S; Hosokawa A; Sakai T; Oda H; Kawahira M; Arita S; Honda T; Taguchi H; Tsuneyoshi K; Kawaguchi Y; Fujita T; Sakae T; Nio K; Ide Y; Ureshino N; Shirakawa T; Mizuta T; Mitsugi K
    Sci Rep; 2024 Jul; 14(1):16906. PubMed ID: 39043707
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens.
    MacEwan JP; Yin W; Kaura S; Khan ZM
    J Manag Care Spec Pharm; 2017 Feb; 23(2):206-213. PubMed ID: 28125374
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.
    Chan KKW; Guo H; Cheng S; Beca JM; Redmond-Misner R; Isaranuwatchai W; Qiao L; Earle C; Berry SR; Biagi JJ; Welch S; Meyers BM; Mittmann N; Coburn N; Arias J; Schwartz D; Dai WF; Gavura S; McLeod R; Kennedy ED
    Cancer Med; 2020 Jan; 9(1):160-169. PubMed ID: 31724340
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
    Schlick K; Gantschnigg A; Seymer A; Huemer F; Greil R; Weiss L
    Cancer Med; 2023 Aug; 12(16):16997-17004. PubMed ID: 37537780
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
    Franco F; Camara JC; Martín-Valadés JI; López-Alfonso A; Marrupe D; Gutiérrez-Abad D; Martínez-Amores B; León A; Juez I; Pérez M; Royuela A; Ruiz-Casado A
    Clin Transl Oncol; 2021 Apr; 23(4):812-819. PubMed ID: 32857340
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
    Bachet JB; Chibaudel B; Bonnetain F; Validire P; Hammel P; André T; Louvet C;
    BMC Cancer; 2015 Oct; 15():653. PubMed ID: 26445094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
    Ghosn M; Ibrahim T; Assi T; El Rassy E; Kourie HR; Kattan J
    World J Gastroenterol; 2016 Dec; 22(46):10124-10130. PubMed ID: 28028360
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
    Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM
    Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
    Chllamma MK; Cook N; Dhani NC; Giby K; Dodd A; Wang L; Hedley DW; Moore MJ; Knox JJ
    Br J Cancer; 2016 Sep; 115(6):649-54. PubMed ID: 27467054
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
    Otsu T; Inokawa Y; Takami H; Hayashi M; Kurimoto K; Tanaka N; Tanaka H; Shimizu D; Hattori N; Kanda M; Tanaka C; Nakayama G; Kodera Y
    Anticancer Res; 2022 Aug; 42(8):3889-3894. PubMed ID: 35896232
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [FOLFIRINOX, nab-paclitaxel + gemcitabine].
    Shimizu S
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():405-8. PubMed ID: 25857057
    [No Abstract]   [Full Text] [Related]  

  • 54. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
    Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
    Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.
    Berger AK; Weber TF; Jäger D; Springfeld C
    Onkologie; 2013; 36(12):763-5. PubMed ID: 24356569
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
    Zaibet S; Hautefeuille V; Auclin E; Lièvre A; Tougeron D; Sarabi M; Gilabert M; Wasselin J; Edeline J; Artru P; Bechade D; Morin C; Ducoulombier A; Taieb J; Pernot S
    Br J Cancer; 2022 Jun; 126(10):1394-1400. PubMed ID: 35094032
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
    Marschner N; Hegewisch-Becker S; Reiser M; von der Heyde E; Bertram M; Hollerbach SH; Kreher S; Wolf T; Binninger A; Chiabudini M; Kaiser-Osterhues A; Jänicke M;
    Int J Cancer; 2023 Feb; 152(3):458-469. PubMed ID: 36053905
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival.
    Dai WF; Habbous S; Saluja R; Beca JM; Raphael M; Arias J; Gavura S; Earle CC; Biagi JJ; Coburn N; Chan KKW
    Clin Oncol (R Coll Radiol); 2023 May; 35(5):e303-e311. PubMed ID: 36863956
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer.
    Cui H; Guan J; Deng G; Yuan J; Lou C; Zhang W; Zhou A; Zhang Y; Zhou J; Dai G
    Med Sci Monit; 2020 Oct; 26():e927654. PubMed ID: 33100319
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure.
    Matsumoto T; Kurioka Y; Okazaki U; Matsuo Y; Kimura S; Miura K; Tsuduki T; Takagi S; Takatani M; Morishita H
    Pancreas; 2020 Apr; 49(4):574-578. PubMed ID: 32282772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.